HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Tempest Therapeutics (NASDAQ:TPST) and maintained a $47 price target.

March 20, 2024 | 10:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Tempest Therapeutics with a $47 price target.
The reiteration of a Buy rating and a maintained price target of $47 by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short-term impact on TPST's stock price. Analyst ratings, especially with a high price target, often signal market optimism around a company's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100